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Abstract
Background: The application of induction chemotherapy failed to provide a consistent benefit for
local control in primary treatment of advanced head and neck (H&N) cancers. The aim of this study
was to compare the results of concomitant application of radiochemotherapy for treating locally
advanced head-and-neck carcinoma in comparison with the former standard of sequential
radiochemotherapy.
Methods: Between 1987 and 1995 we treated 122 patients with unresectable (stage IV head and
neck) cancer by two different protocols. The sequential protocol (SEQ; 1987–1992) started with two
courses of neoadjuvant chemotherapy (cisplatin [CDDP] + 120-h continuous infusions (c.i.) of
folinic acid [FA] and 5-fluorouracil [5-FU]), followed by a course of radiochemotherapy using
conventional fractionation up to 70 Gy. The concomitant protocol (CON; since 1993) combined two
courses of FA/5-FU c.i. plus mitomycin (MMC) concomitantly with a course of radiotherapy up to
30 Gy in conventional fractionation, followed by a hyperfractionated course up to 72 Gy. Results
from the two groups were compared.
Results: Patient and tumor characteristics were balanced (SEQ = 70, CON = 52 pts.). Mean
radiation dose achieved (65.3 Gy vs. 71.6 Gy, p = 0.00), response rates (67 vs. 90 % for primary, p
= 0.02), and local control (LC; 17.6% vs. 41%, p = 0.03), were significantly lower in the SEQ group,
revealing a trend towards lower disease-specific (DSS; 19.8% vs. 31.4%, p = 0.08) and overall (14.7%
vs. 23.7%, p = 0.11) survival rates after 5 years. Mucositis grades III and IV prevailed in the CON
group (54% versus 44%). Late toxicity was similar in both groups.
Conclusion: Concurrent chemotherapy seemed more effective in treating head and neck tumors
than induction chemotherapy followed by chemoradiation, resulting in better local control and a
trend towards improved survival.
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Background
Various approaches have been developed to intensify
standard radiotherapy in locally advanced head and neck
carcinomas, such as altered fractionation schemes (hyper-
fractionation, acceleration) [1] or combination with
chemotherapy [2]. Improved local control and survival
have been confirmed in recent trials of concomitant radi-
ochemotherapy [2-4]. However, three meta-analyses of
radiochemotherapy in advanced head and neck cancer [5]
showed that the impact of chemotherapy on overall sur-
vival is rather small (improving e.g. 5-year overall survival
from 30% to 35%). Compared to radiotherapy alone,
concomitant radiochemotherapy shows the biggest
improvement with respect to local control and disease-
specific survival. As a result, concomitant radiochemo-
therapy with cisplatin and 5-FU is increasingly accepted as
standard treatment for patients with unresectable head
and neck carcinoma and adequate performance status.
To date, no randomised study has compared induction
chemotherapy followed by concurrent radiotherapy
against chemotherapy with a concomitant radiochemo-
therapy schedule. We present such a non-randomised
comparison with respect to late toxicity, local control and
survival in patients with stage IV unresectable head and
neck cancers, who were treated according to two different
schedules at our institution between 1987 and 1995.
Methods
Between March 1987 and July 1995, 122 patients were
treated with two consecutive phase-II protocols in the
departments of radiation oncology and hematology/
Flow sheet of the two treatment regimes Figure 1
Flow sheet of the two treatment regimes. A (top): treatment schema, sequential protocol (SEQ.). B (bottom): treatment 
schema, concomitant protocol (CON).BMC Cancer 2006, 6:30 http://www.biomedcentral.com/1471-2407/6/30
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oncology at the Charité. The first, sequential (SEQ) proto-
col was performed between 1987 and 1992 and included
neoadjuvant chemotherapy with a subsequent radiother-
apy course. The second protocol was performed after 1992
and consisted of concomitant radiochemotherapy with
subsequent hyperfractionation.
The first protocol was approved by the ethical committee
at the Virchow-Klinikum and the second by the ethical
committee of the Campus Charité-Mitte of the Charité.
Eligibility criteria
Patients were eligible if they had primary, histologically
proven, non-metastatic squamous cell carcinoma of the
oral cavity, oropharynx, hypopharynx or larynx, assessed
as unresectable in the department of head-and-neck sur-
gery because of size, extension or location. Patients who
had previously undergone cytostatic therapy or radiother-
apy were excluded, along with those with contraindica-
tions against radiotherapy or the cytostatic agents used (5-
FU, FA, CDDP, MMC). Written informed consent was
obtained from all patients before therapy.
Evaluation of patients
For every patient, clinical, laboratory and imaging exami-
nations were performed to achieve an accurate TNM stage
(UICC, 5th ed.) [6] and to allow follow-up.
During therapy, the patients were examined for acute tox-
icity every week. Acute side effects were indexed according
to EORTC criteria [7]; late side effects were classified
according to the LENT tables [8]. The response (primary as
well as lymph nodes) was assessed by clinical examina-
tion and CT according to WHO criteria [9].
After completion of therapy, each patient was followed up
within 6–8 weeks by an interdisciplinary consultation
involving clinical evaluation (head and neck status) com-
plemented by CT. After specific symptoms or suspicious
findings, diagnostic procedures were extended. Further
follow-up included examinations at intervals extending
from 6 weeks initially to 6 – 12 months after the third
year.
In cases of histologically proven local recurrence, all avail-
able salvage treatment options were offered (brachyther-
apy, hyperthermia, external re-irradiation,
chemotherapy); most often palliative chemotherapy with
MTX (methotrexate) was performed.
Treatment records (fig. 1A+B)
In the first sequential (SEQ) protocol, 2 three-weekly
courses of neoadjuvant chemotherapy were applied, con-
sisting of cisplatin (CDDP; 100 mg/m2 i.v., on day 1) fol-
lowed by 50 mg/m2 folinic acid (day 1) and parallel 120
h continuous infusions of folinic acid (250 mg/m2 per
day, days 1–5) and 5-fluorouracil (600 mg/m2, days 1–5).
Six weeks later (day 43), the third chemotherapy course
was started at a 60% reduced dose concomitantly with the
definitive radiotherapy. External beam radiotherapy was
applied without preference to both groups, with photon
energies of 1.2 MeV (telecobalt unit) or 4–8 MV (linear
accelerator). The primary tumor and regional lymph
drainage areas received 60 Gy in single fractions of 1.8–2
Gy. To shield the spinal cord after achieving a dose of 40
Gy, the dorsal parts of the target volume were treated with
fast electrons of 9-12MeV. Primary tumor and lymph
node areas that were macroscopically involved were
boosted to a total dose of 70 Gy.
In the second, concomitant (CON) schedule, an RCT pro-
tocol was conducted concomitantly with chemotherapy
as in the study of Budach [4,10]. Here, chemotherapy was
initiated with intravenous short infusions of folinic acid
(50 mg/m2, day 1) and 5-FU (350 mg/m2, day 1), fol-
lowed by parallel 120 h continuous infusions with both
drugs (folinic acid, 100 mg/m2 daily; 5-FU, 350 mg/m2
daily). In addition, short infusions of mitomycin C (10
mg/m2) were administered on days 1 and 36. Radiother-
apy began synchronously with chemotherapy, starting
with single doses of 2 Gy up to a total dose of 30 Gy over
the entire affected volume. Gross areas were then boosted
using hyperfractionation, with two daily 1.4 Gy fractions
separated by an interval of at least 6 hours, to a total dose
of 70.6 Gy (10 patients) or 72 Gy (42 patients). Lymph
node regions at low or intermediate risk of subclinical
infiltration were irradiated to total doses of 50 Gy (nor-
mofractionated) or 60 Gy (hyperfractionated after 30 Gy),
respectively. The dorsal paravertebral parts of the target
volume were irradiated with lateral 6–9 MeV electron
fields after 36–40 Gy at the myelon, conventionally frac-
tionated if not clinically involved, hyperfractionated oth-
erwise.
Statistical evaluation
We used the distribution-free Mann-Whitney test to com-
pare the two patient groups (SEQ/CON). A univariate
analysis of prognostic factors was carried out through a
comparison of survival times and local control rates using
the log-rank test. A multivariate analysis was carried out
for all parameters with significant correlations in the uni-
variate analysis according to the proportional-hazard
model. Time-to-progression (TTP), tumour specific and
overall survival were identified from the first day of treat-
ment up to the day of death or last patient contact follow-
ing the Kaplan-Meier method [11]. In particular, TTP was
defined as the time from day 1 of treatment until clinical
progression, i.e. the timing of a more than 25% increase
in post-therapeutic volume (determined 6–8 weeks afterBMC Cancer 2006, 6:30 http://www.biomedcentral.com/1471-2407/6/30
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end of treatment) in any tumor lesion, or histopathologi-
cal validation of recurrent disease after a CR.
Results
Seventy patients in the SEQ group and 52 patients in the
CON group were included in an intent-to-treat analysis.
The median observation times for the surviving patients
were 53 months for the SEQ group and 41 for the CON
group, respectively (for all patients, 19.8 and 14.7 months
in the two groups).
Patients' characteristics
We found a comparable distribution of prognostic factors
in both groups with regard to age, gender and perform-
ance status (WHO). Tumors of the oropharynx predomi-
nated, with frequencies of 54% and 58% in the SEQ and
CON group, respectively (p = 0.66). The percentage of
tumors located in the hypopharynx was found to be
slightly higher in the SEQ group (29% vs. 17% of patients,
p = 0.13). All other tumor characteristics were statistically
equally distributed according to table 1. Most patients had
advanced stages, with T4-categories in 68% vs. 77% (p =
0.28), and N2c-N3 in 44% vs. 43%, of patients in the SEQ
vs. CON groups, respectively. The resulting clinical stages
were as high as IV and V (RTOG) for the majority of the
patients, i.e. 33% and 59% (together 92%) for the SEQ
group and 31% and 67% (together 98%, p = 0.37) for the
CON group.
Treatment parameters
In the SEQ group, 5/70 patients (7%) received only one
chemotherapy course owing to rapid tumor progression
and/or poor performance status. Two courses were
applied to 22/70 patients (31%), and three cycles were
given to only 43/70 (62%). Of these, 65/70 (95%) could
be evaluated for response after induction chemotherapy,
and 62/70 (89%) after the whole treatment course.
Patients who could not be evaluated for response
included three treatment-related deaths during the first
two cycles. At the second checkpoint (after radiotherapy),
4/70 patients were non-evaluable and received no radio-
therapy.
In the CON group, the first course of chemotherapy was
given to all patients with at least 80% of the prescribed 5-
FU dose level. Two of the patients received only one appli-
cation of mitomycin C in week 1 because the whole treat-
ment had resulted in considerable toxicity by week 6.
Table 1: Comparison of patients' characteristics differentiated to the type of schedule
SEQ (sequential, n = 70) CON (concomitant, n = 52) p
Parameter number (%) number (%) 0.80
Age, years
Mean (Range) 53 (37–77) 52.8 (39–66) 0.79
Performance status (WHO) 0.67
0,1 35 (50) 30 (58)
2,3 27 (39) 19 (37)
Unknown 8 (11) 2 (4)
T-stage (UICC) 0.54
T 2 4( 6 ) 3( 6 )
T3 18 (26) 9 (17)
T4 48 (68) 40 (77)
N-stage 0.13
N2c 23 (33) 15 (29)
N 3 8( 1 1 ) 7( 1 4 )
RTOG stage groupings 0.58
III (T3-4 N0, T1-2 N2) 5 (7) 1 (2)
IV (T1-2 N3, T3 N1-2, T4 N1) 23 (33) 16 (31)
V (T4 N2-3) 41 (59) 35 (67)
UICC stage groupings
IV (a + b) 69 (99) 52 (100)
Tumor location 0.19
Oral cavity 7 (10) 10 (19)
Oropharynx 38 (54) 30 (58)
Hypopharynx, Larynx 25 (36) 12 (23)
Mean tumor size (cm) 4.8 4.6 0.46BMC Cancer 2006, 6:30 http://www.biomedcentral.com/1471-2407/6/30
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Only in 1/52 of the patients (2%) was radiochemotherapy
abandoned, so 51/52, i.e. 98%, of the patients were fur-
ther evaluable.
On average, we applied an average radiation dose of 65.3
Gy to the primary tumor in the SEQ group and 71.6 Gy in
the CON group. The corresponding mean radiation doses
at the involved lymph nodes were 58.1 Gy and 69.5 Gy,
respectively. These doses were significantly different in the
two groups (p = 0.00).
In 23/61 (36%) of the patients in the SEQ group, radio-
therapy was interrupted for longer than 1 week, while 14/
61 (23%) had a break for longer than 3 weeks. In contrast,
only 7/51 (14%) of the patients in the CON group had a
break of at least 1 week, and 3/51 (6%) for more than 2
weeks (p = 0.00). In consequence, the average duration of
radiotherapy (if performed) was significantly longer in
the SEQ compared with the CON group (79.9 vs. 43.4
days, p = 0.00).
Toxicity (table 2)
Three treatment-related deaths occurred in the SEQ-group
(due to hematotoxicity), whereas no such serious compli-
cation was found in patients assigned to the CON group.
Acute local toxicity was generally moderate in both
groups, except for severe mucositis, which affected 54% of
patients receiving hyperfractionated radiotherapy in the
CON-group compared with 44% in SEQ group (n.s.).
Regarding late toxicity, lymph edema, mouth dryness and
dysphagia were the most frequently observed grade III
and IV side effects in both groups, as summarized in table
2. The frequency of grade I or II acute toxicity was higher,
Table 2: Acute and late toxicity after radiotherapy and chemotherapy according to RTOG/ECOG and LENT scores (highest level 
given)
SEQ CON
Grade III Grade IV Grade III Grade IV p
n (%) n (%) n (%) N (%)
Acute toxicity (RTOG)
Skin 11 (16) 0 5 (10) 0 n.s.
Mucositis 31 (44) 1 (1) 28 (54) 2 (4) n.s.
Pharynx 9 (13) 1 (1) 9 (17) 1 (2) n.s.
Salivary glands 10 (14) 0 4 (8) 0 n.s.
Late toxicity (LENT scores)
Skin 2 (3) 0 2 (4) 0 n.s.
Subcutis 5 (7) 0 7 (14) 0 n.s.
Mucosa 4 (6) 0 3 (6) 0 n.s.
Salivary glands 7 (10) 0 3 (6) 0 n.s.
P h a r y n x 5( 7 ) 0 4( 8 ) 1( 2 ) n . s .
Larynx 3 (4) 0 2 (4) 0 n.s.
Mandibula 1 (1) 0 0 1 (2) n.s.
Table 3: Comparison of responses in dependency on the schedule
SEQ (n = 70) CON (n = 52)
After 2 cycles 
chemotherapy
After chemotherapy and 
radiotherapy
After chemotherapy and radiotherapy
Primary (%) Nodes (%) Primary (%) Nodes (%) Primary (%) p2) Nodes (%) p2)
Evaluable 93 (65/70) 93 (65/70) 89 (62/70) 86 (60/70) 98 (51/52) 0.02 98 (51/52) 0.00
Complete response 1) ( C R ) 1 17 4 13 34 6n . s . 5 8n . s .
Partial remission 1) (PR) 51 51 26 33 44 n.s. 37 n.s.
CR and PR 63 59 67 66 90 n.s. 94 n.s.
NC, Progressive disease 30 33 21 20 8 n.s. 4 n.s.
1) WHO 
2) compared with response in the SEQ-group after chemotherapy and radiotherapyBMC Cancer 2006, 6:30 http://www.biomedcentral.com/1471-2407/6/30
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as expected, in the CON group. Occurrences of grade I or
II late toxicity proved to be equally distributed.
Response
The complete primary tumor remission (CR) rates were
41% in the SEQ vs. 46% in the CON group, and the par-
tial remission (PR) rates were 26% vs. 44%, respectively.
Response in the lymph nodes was also less frequent in the
SEQ than the CON group (86% vs. 98%). A survey of the
response rates in primary tumors and involved lymph
nodes is given in table 3. The overall differences (CR + PR
+ PD/NC) in response (CON vs. SEQ) were significant for
both the primary tumors (p = 0.02) and the lymph nodes
(p = 0.00), but the single endpoints (CR or PR or PD/NC)
did not show significant between-group differences. Cal-
culations were performed on the total number of eligible
patients, but it is notable that the proportion of non-eval-
uable patients was considerably higher in the SEQ group
(8/70 versus 1/52) and included four patients receiving
no radiotherapy at all (three were treatment-related
deaths). This difference in treatment failure and disrup-
tion is a further criterion in favour of the CON group, but
it is not encompassed by the response analysis.
Local control and survival
Calculations were performed on the eligible patients and
the results are summarised in table 4. The 5-year local con-
trol rate (local-progression-free survival) was significantly
lower in the SEQ-group than in the CON-group according
to fig. 2 (17.6% vs 41%, p = 0.03 with 51 patients vs. 26
patients relapsing locally). Among the patients achieving
complete remission, 29% had recurrences of the primary
and 24% in the lymph nodes in the CON group after 5
years, compared with 55% and 48% in the SEQ group.
The most common site of recurrence in the SEQ-group
was locoregional (90% of progressive patients), whereas
distant metastases (DM) alone or combined with local
failure (LF) occurred very rarely (4% or 6%, DM ± LF). In
contrast, only 73% had LF alone in the CON-group,
whereas 17% of the patients suffered from initial DM (±
LF). Overall, fewer patients in the SEQ-group than in the
CON-group presented with DM (± LF) (actuarially 18% or
26% after 5 years, 6 patients vs. 10 patients). Secondary
cancers occurred in both groups with similar frequencies
(7% and 8%).
The actuarial disease-specific survival curves (fig. 3, table
4) were not statistically different (5 years: 19.8% and
31.4%, with tumor-related deaths of 52 patients and 30
patients), but showed a trend in favour of the CON-group
(p = 0.08). The overall survival curves showed the same
tendency, with 3-year survival rates of 30% vs. 21% and 5-
year survival rates of 24% vs. 15% in favour of the CON-
group (p = 0.11, 56 vs. 36 patients dying from all causes)
(fig. 4).
Predictors of outcome
The prognostic factors that had proved significant in uni-
variate analysis were subjected to multivariate analysis,
which showed that T-categories (≤ T3 vs. T4, p < 0.001)
and N-categories (≤ N2a vs. N2b, N3, p < 0.01) were sig-
nificantly correlated with locoregional control. The type
of treatment protocol had a borderline significant rela-
tionship (p = 0.06) with local treatment outcome. Per-
formance status, RTOG stage and radiation dose proved
not to be significantly correlated in the multivariate anal-
ysis.
Table 4: Comparison of treatment results between the two groups
SEQ CON p
Overall survival (5 ys.) 14.7 % 23.7 % 0.11
Median overall survival 14.6 months 20.1 months
Disease-free survival (5 ys.) 19.8 % 31.4 % 0.08
Progression free survival (5 ys.) years) 17.6 % 41.0% 0.03
Median time to (local) progression 10.7 months 15.0 months
1) WHO 2) compared with response in the SEQ-group after chemotherapy and radiotherapy
Kaplan-Meier survival curves with locoregional control, i.e.  detecting time-to-local progression, in relation to the type of  protocol Figure 2
Kaplan-Meier survival curves with locoregional control, i.e. 
detecting time-to-local progression, in relation to the type of 
protocol.BMC Cancer 2006, 6:30 http://www.biomedcentral.com/1471-2407/6/30
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With regard to disease-specific survival, a multivariate
analysis of the significant prognostic factors from the uni-
variate analysis revealed T-stage (≤ T3 vs. T4, p < 0.001),
N-stage (≤ N2a vs. N2b, N3, p < 0.001), performance sta-
tus (p = 0.04) and treatment protocol (SEQ vs. CON, p <
0.01) as significant predictors. The total dose showed bor-
derline significant correlation (p = 0.06) with disease-spe-
cific survival, whereas there was no significant correlation
for the RTOG stage. N-stage (p = 0.00), treatment protocol
(p = 0.03) and radiation dose (p = 0.05) proved signifi-
cant for overall survival.
Discussion
Radiochemotherapy is becoming increasingly established
as a standard method for treating inoperable head and
neck carcinomas, but the optimal scheme is still under
discussion. One reason is the large variation in risk factors
among patient groups.
It has been found that the percentage of local control after
5 years following a treatment regimen consisting solely of
radiotherapy is improved by adding chemotherapy (5-FU,
cisplatin etc.), which has conferred survival benefit in a
number of trials. Several studies have failed to demon-
strate any influence on the frequency of systemic dissemi-
nation.
We evaluated two different radiochemotherapeutic
approaches to patients with locally advanced head and
neck cancer. Prognostic factors were more or less equally
distributed in the two groups. Clearly, the groups differed
in treatment parameters in concerning radiation dose,
cytotoxic drugs, treatment time, etc. Therefore, it might be
difficult to estimate the influence of a single parameter on
treatment outcome. In our study, improvements in dis-
ease staging and support measures could not have been
major contributors. Treatment technique, treatment plan-
ning and radiation therapy technology were not changed
significantly in our institution during the time encom-
passing the studies on the two groups.
In general, our results suggest that concomitant radioche-
motherapy is superior with respect to local control, but
not unequivocally with respect to distant metastases or
overall survival. The regenerative response of clonogens
may weaken the contribution of induction chemotherapy
to locoregional control. In addition, the toxicity of the
applied dose-intense chemotherapy often impaired the
regular administration of radiotherapy within the SEQ-
group (an attribute of the sequential scheme), resulting in
treatment interruptions that led to a mean treatment time
twice as long as in the CON-group. This shows that the
impairment in quality of life following sequential treat-
ment – in addition to worse results – may be greater than
the adverse effects of concomitant radiochemotherapy.
The 5-year overall survival rates (15% vs. 24%) and 5-year
disease-free survival rates (20% vs. 31%) are relatively low
in both groups, obviously because all except one patient
suffered from stage IV disease, and a high proportion of
patients in both groups had unfavourable prognostic indica-
tors (see table 1). Other investigators report similarly low
overall survival rates for patients with comparably unfa-
vourable prognostic factors [4,12,13].
Better treatment results are achieved with selected collec-
tives. Regarding recent prospective trials, 3-year local con-
trol rates of 50–70% are not uncommon in patients
treated with irradiation and concurrent chemotherapy
(with conventional or altered fractionation) [14]. For
example, Dinges et al. [10] reported a high disease-free
survival rate of 59% and a local control rate of 72% after
4 years using the treatment schedule applied in the CON-
group of our analysis. Overall, most of the published stud-
ies [14] report 2–3 year overall survival rates of around
20–30% following radiotherapy and 40–50% following
concomitant radiochemotherapy [3,14-16], comparable
to our 30–40% 2-3-year survival rate after concomitant
RCT (fig. 5). The difference of about 10% can easily be
explained by the poor prognostic indicators of our (rather
unselected) patient groups. Note that in a large meta-anal-
ysis with more than 10,000 patients, the survival rates for
any kind of locoregional treatment plus chemotherapy
(including radical surgery with adjuvant or neoadjuvant
chemotherapy) were not higher than 36% after 5 years
[5], compared to 24% in our CON group.
Patients with unresectable head and neck tumors have a
limited risk of death from distant metastases, at least in
comparison to patients suffering from gastrointestinal
Kaplan-Meier disease-specific survival curves, i.e. considering  tumor-related deaths, in relation to the type of protocol Figure 3
Kaplan-Meier disease-specific survival curves, i.e. considering 
tumor-related deaths, in relation to the type of protocol.BMC Cancer 2006, 6:30 http://www.biomedcentral.com/1471-2407/6/30
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malignancies. Studies based on autopsies have verified
that 40% of patients with head and neck cancers died
from local relapses without evidence of distant metastases
or secondary primary tumors (32%), whereas only 5% of
patients died from distant metastases alone [17].
Theoretically, neoadjuvant chemotherapy can benefit a
few patients directly (by tumor regression in responders),
but may also reduce the incidence of distant metastases,
especially in collectives with known risk factors. In a
number of clinical studies of induction chemotherapy
[18], neither significant downstaging nor a decreased inci-
dence of distant metastases was observed. In a meta-anal-
ysis, Pignon found no significant benefit from induction
chemotherapy as opposed to concomitant chemotherapy
in head and neck cancer [5]. In our study, local failures
were the most frequent causes of death, and so far as local
control is concerned we found a markedly better outcome
in the CON-group. On the other hand, patients with met-
achronous distant metastases were less frequent in the
SEQ-group.
Randomised studies comparing induction chemotherapy
with subsequent radiotherapy against radiotherapy alone
[2,15] have failed to showany significant advantage in
terms of overall survival and disease-free survival. On the
other hand, concomitant application of cytostatic drugs
has resulted in significant improvement, as shown in sev-
eral randomised trials, independently of fractionation
[2,3,19]. Radiochemotherapy can even improve on radio-
therapy alone with dose escalation [4]. In other studies, a
randomised comparison between hyperfractionated dose-
escalated radiotherapy and hyperfractionated radiother-
apy with concomitant chemotherapy showed only slight
advantages for the combined arm [20]. Only a few studies
have been conducted on randomised comparisons
between concomitant radiochemotherapy (with moder-
ate chemotherapy dosages) and sequential radiochemo-
therapy (with systemically effective chemotherapy
dosages). In this regard, Adelstein [2] reported a signifi-
cant increase in the local control rate using concomitant
RCT. Taylor [21] achieved significantly better disease-free
survival, although overall survival was not significantly
increased.
Conclusion
In comparison with concomitant radiochemotherapy,
induction chemotherapy followed by radiotherapy has
lost popularity. This was confirmed by our retrospective
analysis, i.e. treatment with induction chemotherapy
proved inferior with regard to applicability and efficacy
and resulted in unsatisfactory survival rates and low
patient compliance. Although induction chemotherapy
might result in higher systemic effectiveness, inferior loco-
regional control dominates the clinical outcome. Schemes
using simultaneous chemotherapy and hyperfractionated
radiotherapy generally show greater acute toxicity and bet-
ter overall survival, tumour specific survival, disease-free
survival and local control if patient selection is appropri-
ate. To optimise the combination of both modalities
(radiotherapy and chemotherapy) the aim must be to
achieve higher local effectiveness together with tolerable
acute and late toxicities.
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